Year 2017: top* 10 papers with the highest R-portion

Topic: Cancer Immunotherapy

* The top 5% of entries has been removed to reduce statistical anomalies. Further fine-tuning, filtering, and error cleaning are in progress.

Current Diagnosis and Management of Immune Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitor Therapy

YCR = 2017 / 488 /  15.15 

Randomized, Double-Blind, Phase III Trial of Ipilimumab Versus Placebo in Asymptomatic or Minimally Symptomatic Patients With Metastatic Chemotherapy-...

YCR = 2017 / 593 /  15.14 

Combined antiangiogenic and anti–PD-L1 therapy stimulates tumor immunity through HEV formation

YCR = 2017 / 565 /  15.13 

Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study

YCR = 2017 / 528 /  14.72 

Efficacy and Safety of Nivolumab Alone or in Combination With Ipilimumab in Patients With Mucosal Melanoma: A Pooled Analysis

YCR = 2017 / 460 /  14.56 

Hyperprogression during anti-PD-1/PD-L1 therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma

YCR = 2017 / 485 /  13.75 

Cancer immunotherapies targeting the PD-1 signaling pathway

YCR = 2017 / 497 /  13.70 

DNA Damage and Repair Biomarkers of Immunotherapy Response

YCR = 2017 / 514 /  13.49 

Obstacles Posed by the Tumor Microenvironment to T cell Activity: A Case for Synergistic Therapies

YCR = 2017 / 513 /  13.43 

PD-L2 Expression in Human Tumors: Relevance to Anti-PD-1 Therapy in Cancer

YCR = 2017 / 439 /  13.17